Nonalcoholic Fatty Liver Disease among Long-term Hospitalized Patients with Schizophrenia in a Public Psychiatric Hospital

10.4103/TPSY.TPSY_38_21

Tai-Chi Lee；Bo-Jian Wu；Chuan-Hsun Yu；Tso-Jen Wang

chronic hepatitis B infection ； medications for psychosis ； steatosis of liver ； Taiwan

台灣精神醫學

35卷4期（2021 / 12 / 01）

197 - 202

英文

Objectives: Nonalcoholic fatty liver disease (NAFLD) is a notable chronic liver disease due to metabolic syndrome, which has yet to be explored in long-term hospitalized patients with schizophrenia. In this study, we intended to study the prevalence of NAFLD and related risk factors for patients with schizophrenia who were long-term hospitalized. Methods: All of 182 patients with schizophrenia were recruited from a public psychiatric hospital in Taiwan. Abdomen ultrasonography was carried out for all patients. In addition to age and sex, covariates including medical diagnoses (e.g., hypertension, hypertriglyceridemia, hypercholesterolemia, and diabetes), obesity, one-year cumulative dose of antipsychotics before the entry of this study, and abnormal liver function were included in the logistic regression model. Results: The mean age ± standard deviation (SD) was 50.3 ± 9.2 years. The mean duration ± SD of hospitalization was 8.7 ± 5.0 years. Males accounted for 60.4% (110/182). The percentage of NAFLD was 70.8% (129/182). In multivariate logistic regression, patients' odd ratios (OR) (95% confidence interval [CI]) for a diagnosis of hypertriglyceridemia were 4.3 (1.11-16.7, p ＜ 0.05) and for a finding of obesity 15.8 (3.82-65.6, p ＜ 0.01), were significantly to have NAFLD. But patients with chronic hepatitis B were not significant to have NAFLD (OR [95% CI] = 0.17 [0.05-0.6]). Conclusion: The prevalence of NAFLD was high in patients with long-term hospitalized patients with schizophrenia in this study. We suggest that patients with schizophrenia and with long-term hospitalization need to receive timely, comprehensive, and prompt assessments for the presence of NAFLD as well as that intervention for their NAFLD is mandatory for maintaining well-being and quality of life in them.

1. Abdi, H(2003).Partial least squares (PLS) regression.Encyclopedia of Social Sciences Research Methods,Thousand Oaks, California, USA:
2. Ahmed, MH,Byrne, CD(2009).Current treatment of non-alcoholic fatty liver disease.Diabetes Obes Metab,11,188-195.
3. Assy, N,Kaita, K,Mymin, D(2000).Fatty infiltration of liver in hyperlipidemic patients.Dig Dis Sci,45,1929-1934.
4. Azarkar, G,Doosti, Z,Osmani, F(2019).Analysis of risk factors for nonalcoholic fatty-liver disease in hepatitis B virus infection: a casecontrol study.Hepat Med,11,153-158.
5. Bellentani, S(2017).The epidemiology of non-alcoholic fatty liver disease.Liver Int,37(Suppl 1),81-84.
6. Boppidi, H,Daram, SR(2008).Nonalcoholic fatty liver disease: hepatic manifestation of obesity and themetabolic syndrome.Postgrad Med,120,E01-E07.
7. Chalasani, N,Younossi, Z,Lavine, JE(2012).The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.Gastroenterology,142,1592-1609.
8. Chen, CH,Huang, MH,Yang, JC(2006).Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults.J Clin Gastroenterol,40,745-752.
9. Clark, JM(2006).The epidemiology of nonalcoholic fatty liver disease in adults.J Clin Gastroenterol,40(Suppl 1),S5-S10.
10. Donati, G,Stagni, B,Piscaglia, F(2004).Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance.Gut,53,1020-1023.
11. Franz, M,Meyer, T,Ehlers, F(2002).Schizophrenic patients, who still live in psychiatric hospitals despite decades of deinstitutionalization. Part 1 of the Hessian deinstitutionaisation study.Psychiat,29,245-250.
12. Gardner, DM,Murphy, AL,O'Donnell, H(2010).International consensus study of antipsychotic dosing.Am J Psychiatry,167,686-693.
13. Gupte, P,Amarapurkar, D,Agal, S(2004).Non-alcoholic steatohepatitis in type 2 diabetes mellitus.J Gastroenterol Hepatol,19,854-858.
14. Gurusamy, J,Gandhi, S,Damodharan, D(2018).Exercise, diet and educational interventions for metabolic syndrome in persons with schizophrenia: a systematic review.Asian J Psychiatr,36,73-85.
15. Horacek, J,Bubenikova-Valesova, V,Kopecek, M(2006).Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.CNS Drugs,20,389-409.
16. Hou, XH,Zhu, YX,Lu, HJ(2011).Non-alcoholic fatty liver disease's prevalence and impact on alanine aminotransferase associated with metabolic syndrome in the Chinese.J Gastroenterol Hepatol,26,722-730.
17. Hsu, JH,Chien, IC,Lin, CH(2014).Increased risk of chronic liver disease in patients with schizophrenia: a population-based cohort study.Psychosomatics,55,163-171.
18. Huang, J,Jing, M,Wang, C(2020).The impact of hepatitis B virus infection status on the prevalence of nonalcoholic fatty liver disease: a population-based study.J Med Virol,92,1191-1197.
19. Joo, EJ,Chang, Y,Yeom, JS(2017).Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study.Hepatology,65,828-835.
20. Kistler, KD,Brunt, EM,Clark, JM(2011).Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease.Am J Gastroenterol,106,460-468.
21. Machado, MV,Oliveira, AG,Cortez-Pinto, H(2011).Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients.J Gastroenterol Hepatol,26,1361-1367.
22. Mantovani, A,Petracca, G,Beatrice, G(2021).Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials.Metabolites,11,73.
23. Morlán-Coarasa, MJ,Arias-Loste, MT,Ortiz-García de la Foz, V(2016).Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.Psychopharmacology (Berl),233,3947-3952.
24. Newcomer, JW(2005).Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.CNS Drugs,19(Suppl 1),1-93.
25. Ong, JP,Pitts, A,Younossi, ZM(2008).Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.J Hepatol,49,608-612.
26. Peduzzi, P,Concato, J,Kemper, E(1996).A simulation study of the number of events per variable in logistic regression analysis.J Clin Epidemiol,49,1373-1379.
27. Serfaty, L,Lemoine, M(2008).Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis.Diabetes Metab,34,634-637.
28. Silverman, JF,O'Brien, KF,Long, S(1990).Liver pathology in morbidly obese patients with and without diabetes.Am J Gastroenterol,85,1349-1355.
29. Tsai, CH,Li, TC,Lin, CC(2008).Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease.South Med J,101,900-905.
30. Vancampfort, D,Knapen, J,Probst, M(2012).A systematic review of correlates of physical activity in patients with schizophrenia.Acta Psychiatr Scand,125,352-362.
31. Wong, VW,Wong, GL,Chu, WC(2012).Hepatitis B virus infection and fatty liver in the general population.J Hepatol,56,533-540.
32. Xiong, J,Zhang, H,Wang, Y(2017).Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: a meta-analysis.Oncotarget,8,107295-107302.
33. Xu, H,Zhuang, X(2019).Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review.Neuropsychiatr Dis Treat,15,2087-2099.
34. Yan, J,Hou, C,Liang, Y(2017).The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease.Neuropsychiatr Dis Treat,13,1493-1498.
35. Zhong, GC,Wu, YL,Hao, FB(2018).Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population: a case-control study with propensity score analysis.J Viral Hepat,25,842-852.